Key Highlights

  • CVRx shares were weighed down despite Q2 2026 revenue rising 16% to $15.7 million.
  • U.S. Barostim sales rose 21%, with gross margin expanding to 87%.
  • Q3 guidance of $13.5-$14.5 million came in below $14.7 million a year ago.
  • Continued cash burn also weighed on shares despite reimbursement progress.

CVRx, Inc. (NASDAQ: CVRX) shares were weighed down after the company announced that second-quarter 2026 revenue rose 16% to $15.7 million, with U.S. Barostim sales up 21% and gross margin expanding to 87%.

What Happened

Weak Q3 guidance of $13.5 million to $14.5 million, versus $14.7 million a year ago, along with continued cash burn, weighed on shares despite reimbursement progress from Humana, CPT codes, and CMS IDE coverage.

Market Reaction

Shares fell as investors focused on the sequential guidance decline implied by the Q3 outlook, which points to lower revenue than the prior-year quarter, overshadowing the reported Q2 growth and margin expansion.

Outlook

Continued reimbursement progress from Humana, CPT codes, and CMS IDE coverage, weighed against the softer Q3 guidance and ongoing cash burn, is likely to remain relevant for CVRx's stock going forward.

Why did CVRx shares fall despite Q2 revenue growth?

Shares fell on weak Q3 guidance of $13.5 million to $14.5 million, below the $14.7 million reported a year ago, along with continued cash burn.

How did U.S. Barostim sales perform?

They rose 21% in Q2.

What reimbursement progress did CVRx report?

Progress from Humana, CPT codes, and CMS IDE coverage.